About this trial
Tuberculosis (TB) remains the leading cause of death from a single infectious agent globally, with millions of people still undiagnosed or diagnosed late. Conventional case-finding strategies rely heavily on symptom screening using the WHO Four-Symptom Screen ((W4SS; comprising any one of current cough, fever, night sweats, or weight loss) and sputum testing, but these approaches miss a substantial proportion of individuals with active TB disease, particularly those who are asymptomatic or unable to produce sputum. Missed and delayed diagnoses drive ongoing transmission and undermine global TB elimination goals.
Recent evidence has shown that diagnostic tools which are more accessible, even if somewhat less sensitive, can still substantially improve TB case detection by reducing diagnostic loss associated with access barriers. This suggests that near point-of-care (NPOC) tests might be highly cost-effective in many settings, because the gains from earlier diagnosis, reduced delays, and broader reach could outweigh losses from slightly lower accuracy.
The purpose of this study is to evaluate new, symptom-agnostic screening and diagnostic approaches that can be implemented at lower-level health facilities in high TB-burden, low and middle-income (LMIC) countries for adults ≥15 years and 10-14 years old young adolescents
Eligibility criteria
Qualifiers
Age
Adults aged 15 years and above or
Adolescents aged 10-14 years
Facility setting
Disqualifiers
Age
Screening eligibility
Consent and follow-up
Current TB treatment
Trial design
Treatments tested in this trial
- Near point of care (NPOC) NAATs
- Low-complexity nucleic acid amplification tests (LC-NAATs)
- LC-NAAT using pooled testing
- Portable Chest X-ray Image Acquisition
- Computer-Aided Detection (CAD) Chest X-ray (CXR-AI)
- Screen TB&HIV sub-study diagnostic test
- Screen TB&HIV sub-study diagnostic test
- Screen TB&HIV sub-study diagnostic test